Usfda Approves Injectable Form Of Gsk Hiv Prevention Drug

The Injection - Apretude - To Prevent The Virus That Causes Aids Is Aimed As An Alternative To Daily Pills And Has Been Approved For Use In At-Risk Adults And Adolescents U.S. Food And Drug Administration (Fda) On Monday Approved An Injectable Form Of Glaxosmithkline Plc'S Cabotegravir Drug That Is Given Every Two Months To Prevent An Hiv Infection. The Injection - Apretude - To Prevent The Virus That Causes Aids Is Aimed As An Alternative To Daily Pills And Has Been Approved For Use In At-Risk Adults And Adolescents. Its First Two Doses Are Administered One Month Apart And Then The Injection Is Given Usfda Approves Injectable Form Of Gsk Hiv Prevention Drug, Health News, Food And Drug Administration Oral Pills Hiv Test Health News Glaxosmithkline Plc Aids Every Two Months Thereafter. Patients Can Start Their Treatment With Apretude Or Take Oral Cabotegravir For Four Weeks To Assess How Well They Tolerate The Drug. Apretude Comes With A Boxed Warning To Not Use The Drug Unless A Negative Hiv Test Is Confirmed. A Boxed Warning On The Label Is Fda'S Strictest Warning And Calls Attention To Serious Or Life-Threatening Risks Of A Drug. Apretude'S Approval Was Based On A Final Study Showing It Was Found To Be 66% More Effective In Preventing Hiv Infections Than Gilead'S Truvada Daily Oral Pills. Cabotegravir And The Daily Oral Pill Were Both Well Tolerated In The Study, Which Was Conducted On Men Who Engage In Sexual Activity With Other Men And Transgender Women Who Have Sex With Men, Putting Them At Risk Of Contracting Hiv

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!